Oral doxercalciferol therapy for secondary hyperparathyroidism in a peritoneal dialysis patient
S.M. Sprague, L.T. Ho Department of Medicine, Evanston Northwestern Healthcare, Northwestern University Medical School, Evanston, Illinois, USA
DOI 10.5414/CNP58155
Abstract
Control of hyperphosphatemia and the administration of vitamin D are the primary treatment modalities for the prevention and management of secondary hyperparathyroidism. Vitamin D therapy for secondary hyperparathyroidism has been limited by the development of hypercalcemia and/or hyperphosphatemia due to increased intestinal absorption of these minerals. Recently, selective vitamin D analogs specifically designed to suppress parathyroid hormone (PTH) without causing hypercalcemia or hyperphosphatemia have shown promise for the treatment of secondary hyperparathyroidism in uremia. This case report describes the successful use of doxercalciferol to treat severe secondary hyperparathyroidism in an adult male patient undergoing chronic peritoneal dialysis, with a follow-up period of 9 months. During this period, the patient?s hyperparathyroidism was rapidly and easily controlled. Treatment was complicated by a single incident of over suppression of PTH, with concomitant hypercalcemia. This quickly resolved upon temporary discontinuation of doxercalciferol therapy, after which therapy was resumed without further incident.
Department of Medicine, Evanston Northwestern Healthcare, Northwestern University Medical School, Evanston, Illinois, USA
Address
Citation
S.M. Sprague and L.T. Ho.Oral doxercalciferol therapy for secondary hyperparathyroidism in a peritoneal dialysis patient .2002; 58: 155-160. doi: 10.5414/CNP58155.
during a check of our data we have observed, that we don't have your current E-Mail address on file. We would like to ask you to send it to us, in case we need to contact you. You can send us an E-Mail to [email protected] or call us under +49-89-613861-0.
